KRAS and neoplasm: Recently, studies have shown that Kras-mutant-bearing cancers display features with reduced T helper 1 cells as well as reduced infiltration of cytotoxic cells via recruiting the myeloid-derived suppressor cells, which made Kras-mutant tumor resistant to immune checkpoint blockade (ICB) therapy (43).